{
    "title": "Biogen confident in Alzheimer's drug ahead of rivals' data",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11352385/Biogen-raises-year-profit-forecast-cost-control.html",
    "date": "2022-10-25",
    "keywords": [
        "biogen",
        "drug",
        "lecanemab",
        "profit",
        "bhanvi",
        "satija",
        "market",
        "disease",
        "month",
        "brain",
        "singhal",
        "efficacy",
        "quarter",
        "lack",
        "share",
        "inc",
        "tuesday",
        "ltd",
        "co",
        "progress",
        "trial",
        "data",
        "belong",
        "class",
        "beta",
        "cause",
        "research",
        "chief",
        "priya",
        "safety",
        "type",
        "swelling",
        "aria",
        "inline",
        "forecast",
        "part",
        "company",
        "infrastructure",
        "launch",
        "aduhelm",
        "controversy",
        "coverage",
        "health",
        "view",
        "network",
        "time",
        "officer",
        "michael",
        "eisai",
        "partnership",
        "approval",
        "decision",
        "sclerosis",
        "treatment",
        "tecfidera",
        "growth",
        "spinraza",
        "disorder",
        "spinal",
        "atrophy",
        "competition",
        "novartis",
        "newer",
        "base",
        "business",
        "decline",
        "analyst",
        "evan",
        "seigerman",
        "commercialization",
        "street",
        "update",
        "search",
        "executive",
        "michel",
        "vounatsos",
        "helm",
        "replacement",
        "reporting",
        "bengaluru",
        "editing",
        "bill",
        "berkrot"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}